Table 1

JAK-STAT inhibitors

JAK-STAT inhibitors
Name	Study	UC/Crohns	Mechanism of Action	Authors	Results	Adverse events
Upadacitinib	U-EXCEED (NCT03345836) U-EXCEL (NCT03345849)	Phase III/Phase III	JAK-1 inhibitor (but with greater selectivity for Jak-1)	Sandborn et al, 202013 Vermeire et al, 2021.12 Danese et al, 202111	CD→Clinical Remission in 49% vs placebo (29%) at Week 12	Acne, Elevated CPK, Nasopharyngitis, Neutropenia/Lymphopenia
Upadacitinib	U-ACHIEVE U-ACCOMPLISH	Phase III/Phase III	JAK-1 inhibitor (but with greater selectivity for Jak-1)		UC→Clinical remission in 26.1% vs 4.8% of placebo and endoscopic remission in 13.7% vs 1.3% at Week 8
Filgotinib	FITZROY	Phase III/Phase III	JAK1, JAK3 and tyrosine kinase 2 inhibitor	Vermeire et al, 201715	CD→47% achieving clinical remission at Week 10.	Infections Herpes Zoster, PE, Malignancy (Non melanoma skin cancer), Impaired Spermatogenesis
Filgotinib	SELECTION	Phase III/Phase III	JAK1, JAK3 and tyrosine kinase 2 inhibitor	Feagan et al, 202116	UC→Significant clinical remission (26.1%) vs placebo (15.3%) at Week 10
Brepocitinib, ritlecitinib	VIBRATOstudy ClinicalTrials. gov identifier: NCT02958865	Phase IIB/Phase IIA	Dual TYK2/JAK1 inhibitor, binds to the active site in the catalytic domain	Sandborn et al, 202117	CD→Awaited
Brepocitinib, ritlecitinib	ClinicalTrials. gov identifier: NCT03395184	Phase IIB/Phase IIA			UC→Clinical and endoscopic remission at Week 8